Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.

Messoud AshinaStewart J TepperUwe ReuterAndrew M BlumenfeldSusan HutchinsonJing XiaRosa MiceliLawrence SevertMichelle FinneganJoel M Trugman

Published in: Headache (2023)

Daily use of oral atogepant 60 mg for preventive treatment of migraine during this 1-year, open-label trial was safe, well tolerated, and efficacious.

Keyphrases

open label
phase iii
phase ii
clinical trial
study protocol
double blind
phase ii study
physical activity
randomized controlled trial
squamous cell carcinoma
placebo controlled
cross sectional
replacement therapy